Gene therapy holds promise for treating previously untreatable retinal disorders. The most promising approaches use gene transfer vectors derived from adeno-associated virus (AAV) to supplement a gene function in the affected cell type. One example is gene therapy for achromatopsia which affects daylight vision. In this case, recombinant AAV (rAAV) vectors are being developed to specifically target cone photoreceptors. Development of rAAV vectors could be facilitated by the use of in vitro models. In this chapter we provide a protocol which utilizes mouse 661W cells, an in vitro model of cone photoreceptors for evaluation of the transduction efficacy of rAAV vectors.
CITATION STYLE
Wagner, J. E., Schön, C., Becirovic, E., Biel, M., & Michalakis, S. (2019). In Vitro Evaluation of AAV Vectors for Retinal Gene Therapy. In Methods in Molecular Biology (Vol. 1834, pp. 383–390). Humana Press Inc. https://doi.org/10.1007/978-1-4939-8669-9_24
Mendeley helps you to discover research relevant for your work.